# OnCo record moxetumomab-pasudotox (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/moxetumomab-pasudotox/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "moxetumomab-pasudotox" ;
  schema:name "Moxetumomab pasudotox"@en ;
  schema:description "An immunotoxin for hairy cell leukaemia that produced lasting remissions in relapsed patients but was withdrawn from sale in 2023 for commercial reasons."@en ;
  schema:url <https://onco.cc/drugs/moxetumomab-pasudotox/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Moxetumomab_pasudotox> ;
  owl:sameAs <http://www.wikidata.org/entity/Q14605217> ;
  schema:citation <https://en.wikipedia.org/wiki/Moxetumomab_pasudotox> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill" ;
  onco:modality "Anti-CD22 immunotoxin (Pseudomonas exotoxin A fragment)" ;
  schema:alternateName "Lumoxiti" ;
  onco:approval "US 2018: Relapsed/refractory hairy cell leukaemia after ≥2 systemic therapies including a purine analogue" ;
  onco:cancers <https://onco.cc/cancers/hairy-cell-leukemia/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cd22/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/pivotal-trial/> ;
  onco:trials <https://onco.cc/trials/nct01829711/>, <https://onco.cc/trials/nct02338050/> .